First manufacturer of medical devices, DHG (Direct Healthcare Group) recorded a growth of 49.7% of its turnover for its last financial year.
A world leader in the manufacture and supply of medical devices for patients whose lives are affected by reduced motion, DHG provides pressure ulcer prevention, moving and material handling equipment, specialist therapies and safety solutions for pressure ulcers. bathrooms to hospitals, acute care environments, nursing homes and homes. houses.
Despite a difficult economic environment, the company achieved sales of £85m (€102.1m) over the past 12 months (compared to sales of £59.8m (€68.2m) €) the previous year for 2020), attributing the growth to strong performance across its rental and service and safe moving and handling divisions, and the launch of six new products, as well as continued execution of its strategic acquisition strategy.
Founded in 2009, DHG currently holds a 15% market share in Europe for its category, with a direct presence in five European countries and additional distribution in 35 countries in Asia, North America and Australasia. The company received the Queen’s Award for Enterprise in International Trade in 2021.
In the UK, it supplies more than 56,000 specialist mattresses each year to 39 NHS Trusts and private facilities across the UK, in addition to providing rentals and emergency equipment.
The company’s stellar performance follows multiple acquisitions, including Dutch patient handling solutions maker United Care BV and UK manufacturer Talley Group Ltd, in March 2021. It plans to make further acquisitions over the course of next year.
Graham Ewart, CEO of DHG comments on the company’s success,
“Despite economic and industry turbulence, we have successfully navigated the environment to approach 2022 in a stable and successful position. We are now a truly international group with pan-European operations, and our growth over the past 12 months is testament to our strategy.
“We experienced the typical seasonal peaks in the fall and winter, and while we encountered logistical challenges following the supply chain crisis in the third quarter, I am delighted that we were able to overcome them with a minimal impact on our results.
“Our range of services and rentals continues to grow and, exacerbated by the Covid-19 pandemic, remains the fastest growing part of the business in the UK.”
Forecasting further growth for 2022, Ewart confirms that the company will build on the successful launch of its SMARTresponse system and double down on innovation in its R&D department over the next 12 months.
He keeps on,
“As market leaders, we will continue to drive innovation and the generation of clinical evidence in the treatment of patients, investing more in our R&D department and recognizing its critical importance to DHG’s growth.
“Our revolutionary Dyna-Form SMARTresponse is a new product that perfectly demonstrates how the integration of technology can advance the healthcare industry. It not only supports clinical time constraints and assists those on the frontlines of our industry through its remote capabilities, but simultaneously delivers best-in-class care for the patient.
“In addition to our continued commitments to ESG and ensuring that sustainability plays a central role in our business, our geographic expansion also continues. We are looking forward to increasing our position in the field of pressure ulcer prevention in our main European markets, in particular in the Netherlands and in the Nordic countries which we believe have enormous potential.
“I am very pleased with the strong position in which we started the year, and we remain on track to become number one in Europe in enabling patient mobility and independence.”
DHG employs over 600 people at its headquarters in Caerphilly (Wales) and in five other European countries in which it has a direct presence.